于健，北京航空航天大学医学科学与工程学院教授、博士生导师，北京市生物医学工程高精尖创新中心高级研究员，入选“医工百人”计划。博士毕业于清华大学医学院，曾任加州大学圣迭戈分校博士后及项目研究员。聚焦癌症、免疫及神经等重大疾病，长期从事基于医工交叉融合的逆向转化医学研究，构建了从“病理探究→药物发现→疗效评价→机制解析”的完整研究体系。在靶向治疗方面：揭示了乳腺癌干细胞抑制剂盐霉素抑制慢性淋巴细胞白血病的新机制；阐明了ROR1促肿瘤机制并开发靶向抗体药，获FDA临床试验批准；解析了依鲁替尼的耐药机制并提出了ROR1抗体药物与依鲁替尼联用的新策略。在免疫治疗方面：利用单细胞测序揭示了接受CD7 CAR-T细胞治疗患者外周免疫重建的动态特征；证实了CD22 CAR-T细胞表面PD-L1表达会削弱其抗肿瘤能力。在跨学科合作方面：联合开发了靶向治疗三阴性乳腺癌的膜包裹多活性铁硫纳米诱导剂。
1. Wang Y., Yu J#, Gao L#. Targeting Intratumoral Bacteria for Cancer Nanotherapeutics. ACS Appl Mater Interfaces 2025. 10.1021/acsami.5c16720.（IF=8.2）
2. Wang Y, Wang X, Zheng Q, Fu Z, Jiang J, Yu J#, Gao L#. Targeted therapy for triple-negative breast cancer via a membrane-encased multi-active iron-sulfur nanoinducer. Nano Research 2025; 18: 94907969.（IF=9.0）
3. Feng X, Chen B, Yang Y, Dong L, Liu C, Yang Y, Hou P, Zheng D, Wang C, Kong Y, Yu J#, Sui L#. CD34 in preeclampsia: The role of endothelial cell pyroptosis and regulation by melatonin via melatonin membrane receptor 1. Int J Biol Macromol. 2025; 318: 145188.（IF=8.5）
4. Liu Z, Wu C, Yao Z, Wang Y, Yu Z, Yu J. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma. Med. Nov. Technol. Devices 2024; 22: 100295.（中国科技期刊卓越行动计划高起点新刊; ESCI）
5. Liu Z, Yu J#, Zhao ZJ#, Shi H#, Kashyap MK#. Editorial: Linking cellular metabolism to hematological malignancies, volume II. Front Oncol. 2024; 14: 1387249.（IF=3.3）
6. Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, Wu Y, Xia Y, Ou Y, Li R, Zhang T, Zhang J, Ke X, Hu K, Yu J. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clin Cancer Res. 2023; 29(8): 1484-1495.（IF=10.2）
7. Liu J, Liu Z, Zhang J, Chen X, Chen J, Sui L, Yu J. Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. Pharmaceutics 2022; 14(9): 1876.（IF=5.5）
8. Liu J, Zhang F, Yu J#, Zhao Q#. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. MedComm 2022; 3(2): e140.（IF=10.7）
9. Liu Z, Liu J, Zhang T, Li L, Zhang S, Jia H, Xia Y, Shi M, Zhang J, Yue S, Chen X, Yu J. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. BMC Cancer 2021; 21(1): 732.（IF=3.4）
10. Zhang D, Guo Y, Zhao Y, Yu L, Chang Z, Pei H, Huang J, Chen C, Xue H, Xu X, Pan Y, Li N, Zhu C, Zhao ZJ, Yu J#, Chen Y#. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021; 20(1): 67.（IF=4.9）
11. Liu J, Yan W, Liu Z, Han Y, Xia Y, Yu J. A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination. Med. Nov. Technol. Devices 2021; 11: 100084.（中国科技期刊卓越行动计划高起点新刊; ESCI）
12. Liu Z, Liu J, Zhang T, Shi M, Chen X, Chen Y, Yu J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151: 104512.（IF=10.5）
13. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia 2017; 31(6): 1333-1339.（IF=13.4）
14. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017; 31(12): 2608-2614.（IF=13.4）
15. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016; 126(2): 585-598.（IF=13.6）
16. Lu D#, Choi MY#, Yu J#, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011; 108(32): 13253-13257.（IF=9.1）
1. Thomas J. Kipps, Jian Yu; Modulators of ROR1-ROR2 binding, 2025-04-29, 美国, US12286480B2.
2. Thomas J. Kipps, Jian Yu, et al.; Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis, 2024-12-10, 美国, US12162950B2.
3. 于健，刘佳，刘卓君；依鲁替尼作为血管抑制剂的作用、降低其副作用的药物及其用途，2020-07-13，中国，ZL202010668072.9。